Clostridium difficile is the leading nosocomial infection in the U.S and a major concern for VA acute and long- term care facilities. The current therapies for C. difficile infection (CDI) target C. difficile bacterium with antibiotics. But this can leads to killing of commensal bacteria and thus reduce colonization resistance to C. difficile which can in turn promote recurrent CDI. Thus, microbiota sparing approaches for CDI therapy are urgently needed. Magnitude of host neutrophilia is a key regulator of disease outcomes after CDI. We have previously reported a key role for leptin-leptin receptor (LEPR) axis in regulating CDI-induced neutrophilia: our studies revealed that a SNP in LEPR (Q223R), which is present in up to 50% of humans, regulates neutrophil numbers in both mice and patients with CDI. Homozygosity for the mutant LEPR allele (RR genotype) was associated with increased neutrophil counts along with significant tissue damage and higher mortality during acute CDI, but earlier resolution of tissue neutrophilia and clinical disease. Since heterogenous neutrophil populations that contribute to both tissue damage and tissue are critical in regulating infectious disease outcomes, we postulate that different neutrophil types develop in response to C. difficile and contribute to tissue damage and repair. We now have compelling preliminary data that reveals distinct neutrophil populations in bone marrow and colonic tissue of C. difficile infected mice. We have defined these populations based on intra-cellular granules (side scatter on FACS) and ?2 integrin (CD11b) expression. In RR mice, an increase in the number of tissue neutrophils (total as well as the activated population, SSChiCD11bhi cells) during acute phase of CDI correlated strongly with severe tissue damage and clinical disease. Subsequently, decline in tissue neutrophils (both total and activated population) was associated with less severe intestinal pathology and earlier recovery from clinical disease in these mice. Further, commensal gut microbiota play an important role in the generation of different neutrophil populations and their mobilization from bone marrow compartment of mice. Our central hypothesis is that LEPR Q to R change is associated with alterations in the gut microbiome that influence the effect of neutrophils on tissue responses to C. difficile in a STAT3-dependent manner. We now propose to comprehensively define the evolution of neutrophil populations during the course of CDI and understand the mechanisms by which LEPR SNP and gut microbiota associated with the SNP regulate formation of distinct neutrophils after CDI. We will answer the following main questions: 1) What are the functional and phenotypic characteristics of neutrophils formed during acute and resolution phase of CDI in both patients and mice with the QQ and RR genotype? 2) How do these neutrophils induce colonic tissue damage and regulate CDI pathogenesis? 3) What is the role of specific gut bacteria in regulating the development of such neutrophil populations? 4) What are the signaling pathways downstream of LEPR that regulate neutrophil heterogeneity after CDI? The goal of our studies is to identify pathogenic and resolution promoting neutrophil subsets during the course of CDI and understand the mechanisms of their development. Identification of the tissue damaging and reparative neutrophil types after CDI has the potential to identify new microbiota-sparing targets for the design of future CDI therapies. In addition, understanding the role of a common human genetic variant in regulating neutrophil heterogeneity and CDI outcomes can be used in precision medicine approaches where LEPR SNP is utilized as a novel genetic biomarker for risk stratification of CDI patients.
Clostridium difficile infection (CDI) is categorized as one of the top 3 ?urgent? public health threats that cost an estimated $4.8 billion/year to the US healthcare system. In both VA acute and long- term care facilities, CDI has a high prevalence (up to 0.66 cases/100 admissions) and substantial morbidity and mortality. Exaggerated host neutrophilia is a key driver of CDI severity and worsens clinical outcomes. We have defined a neutrophil population induced during CDI that correlates with worse intestinal injury and mortality. This pathogenic neutrophil population is enriched in the presence of a common host genetic polymorphism. We now propose to examine the mechanisms by which these pathogenic neutrophils develop and how they cause tissue damage in CDI. Our long-term goal is to identify new host-directed and microbiota sparing targets for CDI therapy.
